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The past few decades have witnessed a global proliferation of
medical research including multicentre, international and
pharmaceutical studies.1 South Africa, with its sound
infrastructure, medical expertise in science and technology and
well-equipped research institutions, is a country of immense
research potential. While the clinical research industry has
existed in South Africa for about 30 years, it has experienced
rapid growth over the past decade,2 increasing by 40% between
1997 and 1998,3 with the total budget during 2000 being in the
region of R826 million (M Joffe – unpublished data). Reasons
for this include researchers being able to meet patient
recruitment timelines and targets consistently. More recently,
South Africa has been viewed as a valuable ‘gateway’ for
launching clinical research efforts northwards into the rest of
Africa.2 In addition, in 2003 South Africa was rated 4th as a top
international National Institutes of Health (USA) grant
recipient by country, with Canada, the UK and Australia in 1st,
2nd and 3rd places respectively2 (see Table I for an example of
the increasing number of reviews at an institutional level).    
While South Africa has a climate conducive to serious
growth in research, it is also home to a large number of
vulnerable groups of poor populations who have limited or no
access to education and health services and who accept
authority without question.4,5 Fifty per cent of South Africans
live below the poverty line.6 As a country we suffer from
several of the health burdens of a developing nation and are
still recovering from the many years of oppression under
apartheid. This, together with previous tragedies, makes clear
that potential for misuse of power in research cannot be
ignored. Accordingly, the promotion of high ethical standards
to protect participants in research is imperative. Currently,
research ethics committees (RECs) are assigned this duty.
However, protecting participants in research has not kept pace
with the rapid growth of research.    
Historical perspective
That medical research has resulted in improved well-being
cannot be disputed. However, over time, medical research has
also violated the rights and dignity of participants, with the
first transgressions being documented in the 19th century.7
Many of the now well-known brutalities on Jews and other
victims in the name of medical research were exposed in the
aftermath of World War II during the Nuremberg Trials, and by
the late 1960s medical research had undergone several scandals
and tragedies.7 Beecher’s landmark article ‘Ethics and clinical
research’8 in 1966 in the New England Journal of Medicine
resulted in ethical issues in research receiving much more
attention. Twenty-two studies that violated the basic standard
of ethical research with human beings were described. These
studies were performed by respected researchers at leading
medical institutions and were published in reputable medical
journals. Reports in 1972 revealed extensive violations of
human rights in the Tuskegee Syphilis Study which was
initiated in Alabama in 1932.9
South Africa has also had its fair share of scandals. While 
the Truth and Reconciliation Commission in 1994 did not
specifically address research issues, it highlighted the human
rights violations inflicted on many South Africans by members
of the medical fraternity, some of whom were active
researchers.10 In December 1990, randomised trials assessing
the efficacy of high-dose chemotherapy in metastatic and high-
risk primary breast cancer were begun by Werner Bezwoda at
the University of the Witwatersrand. Impressive results,
showing that patients in the high-dose group had survival
significantly superior to that in the standard-dose group, were
presented at two international oncology meetings in 1999.
Some oncologists adopted the Bezwoda approach as standard
therapy and an onsite review of his data was undertaken
before embarking on an international multicentre confirmatory
trial. Sadly, the review revealed vast disparity between the
records and the data presented at the international meetings,
there was no signed informed consent and the institutional
REC had no record of the study being submitted for ethics
clearance.11
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The global proliferation of medical research has imposed a huge
responsibility on research ethics committees (RECs). While South
Africa has a climate conducive to serious growth in research, it is
also home to a large number of vulnerable groups of poor
populations. The potential for misuse of power in research cannot
be ignored. Stipulations within the National Health Act now make
the ethical practice of research a statutory requirement in South
Africa. Commitment to REC support by institutions will be
reflective of their commitment to ethical research. However,
currently RECs are overworked and understaffed. Regrettably,
protecting participants in research has not kept pace with the rapid
increase of research in the country.
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Research participant protections –
process
In response to Beecher’s landmark paper, from 1966, individual
institutions in South Africa constituted review bodies to
appraise the ethical aspects of research, and provide ethics
clearance before undertaking research.12 However, while there
are various codes elucidating fundamental protections and
oversight bodies to guide the ethical practice of research,
exploitation of participants’ vulnerabilities has continued, as
evidenced by the above examples.  
In 1998, a process to develop guidelines to promote good
practice and standards in the conduct of clinical trials in South
Africa was started by the National Department of Health. This
resulted in the production of a conceptual framework by the
end of 1998, and a final document in 2000, ‘The Clinical Trials
Guidelines’, guided by and based extensively on international
documents.13
In 2000 the Interim Ministerial Committee on Health
Research Ethics was appointed and it has functioned since to
review the guideline documents of 2000 and to act in an
advisory capacity to local RECs. The National Health Act14
requires the establishment of the National Health Research
Ethics Council (NHREC), its functions being to: ‘a. determine
guidelines for the functioning of health research ethics
committees; b. register and audit health research ethics
committees; c. set norms and standards for conducting research
on humans and animals, including norms and standards for
conducting clinical trials; d. adjudicate complaints about the
functioning of health research ethics committees; e. hear any
complaint by a researcher who believes that he or she has been
discriminated against; f. institute disciplinary action against
any person found to be in violation of any norms and
standards, or guidelines, set for the conducting of research; and
g. advise the national department and provincial departments
on any ethical issues concerning research.’ 
The Act further affirms that every institution, health agency
and health establishment at which health research is conducted
must either establish or have access to a health REC, which is
registered with the National Health Research Ethics Council.
Hence ethical practice of research is now a statutory
requirement in South Africa.15 Moreover, the emphasis on
RECs, together with the need for central audit, clearly implies
that these committees may be viewed as the main protectors of
human research participants. If implemented appropriately,
central registration could also lead to systematic collection and
dissemination of performance data. Currently, records are
lacking on the number of health-related projects and people
participating in health-related research in the country, the
number of research participants suffering serious adverse
events each year, and the number who sustain permanent
disabilities or die unexpectedly from their involvement in
research. 
Research participant protections – some
challenges      
While recent legislative changes mandate ethical rigour in
research, there are challenges to implementation. Financial
implications of protections programmes may result in RECs not
doing justice to their protections role. This is true even in
resource-rich regions. Deficiencies in institutional review board
(IRB) procedures led to the suspension of clinical trials
programmes at several institutions in the USA. Strengthening
these processes increased their operational costs substantially.16
While there has been some mobilisation in the USA to address
meaningful reform, including federal oversight, IRB members
continue functioning under demanding conditions, juggling
IRB membership with numerous other responsibilities. This,
together with a lack of recognition of their communal
contributions, communicates to them a devaluation of their
commitment to ethical research. Not only is this demoralising
to IRB members, but there are damaging implications on a
practical level as chairs of these bodies have difficulty securing
and retaining qualified members. In addition, lack of resources
compromises administrative and support staff.17 Currently,
South African RECs, with their increasing workload, find
themselves in a similar situation. Nevertheless, increased
research is usually commensurate with increased funding to
institutions that have an obligation to apportion part of this to
REC support. It will require more than just legislative changes
to ensure research participant protection. 
Table I. Breakdown of protocol reviewed by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal
over a 5-year period*  
2004 2003 2002 2001 2000
Investigator-driven studies (N) 186 166 116 97 108
Studies for higher degrees (N) 65 39 36 37 29
Industry-related trials (N) 23 35 29 27 36
Total studies reviewed (N) 274 240 181 161 173
* The author thanks Cheryl Borresen (administrator University of KwaZulu-Natal Biochemical REC) for facilitating access to the figures in the protocol breakdown.  Permission was
obtained for use of these data from the REC on 1 March 2005.
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Among the multiple duties of RECs is the post-approval
responsibility of monitoring approved protocols. Lack of REC
support also means that in most instances the committees are
unable to fulfil this obligation adequately. Post-approval
monitoring includes annual review, consent monitoring,
monitoring of adherence to protocol and monitoring of data
integrity.18 Many problems uncovered with current research
practices arise after continuing review and might have been
avoided with thorough and careful monitoring and continuing
review.17
Conflicts of interests involving RECs can occur at multiple
levels. It has been suggested that by virtue of their constitution
and location RECs in academic institutions are remarkably
close to the scientific community whose research they review.
This could possibly result in institution and investigator
protection at the expense of subject protection.19,20 RECs need to
protect and maintain their independence within organisational
structures so as to reduce the risk of compromising participant
protections in favour of institutional interests.21
Conclusion
The need for registration with the NHREC, and the stringent
requirements for accreditation, means that the REC can no
longer be regarded as ‘just another administrative committee’
within the institution. The National Health Act has set the rules
for research involving humans. REC accountability is no longer
limited to the institution only. The time has come for
appropriate recognition and support to be accorded to RECs
and research ethics as a discipline if RECs are to function as
protectors of human research participants.
This paper was initially developed while the author was a
student in the Diploma programme offered by the University of
Cape Town’s International Research Ethics Network for Southern
Africa (IRENSA), funded by the Fogarty International Center of the
US National Institutes of Health.
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